linjc16/ctgov huggingface dataset:
Evolution of Dyspnea After Bariatric Surgery in Patient With Obesity

Study Overview
=================
Brief Summary
-----------------
Obesity, defined as a Body Mass Index greater than or equal to 30 kg/m2, represents a significant public health issue. Dyspnea is a very common and crippling symptom in obesity. About 80% of people with obesity experience dyspnea in daily living. Bariatric surgery has been demonstrated to be an excellent treatment for obesity by inducing significant weight loss. Nevertheless, changes in dyspnea in daily living after bariatric surgery and the links between variations in dyspnea and lung function tests after bariatric surgery have not been previously investigated.

Detailed Description
-----------------
The objective of this study was to determine if bariatric surgery is associated with an improvement of dyspnea in daily living according to the mMRC scale in patients with obesity.

Official Title
-----------------
Evolution of Dyspnea After Bariatric Surgery in Patient With Obesity

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Other: Dyspnea evaluation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Obesity scheduled bariatric surgery Exclusion Criteria: - age < 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with bariatric surgery for obesity<br> | Other: Dyspnea evaluation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dyspnea in daily living evaluated using the mMRC scale | Dyspnea in daily living evaluated using the mMRC scale | Month 6 | 
| Dyspnea in daily living evaluated using the mMRC scale | Dyspnea in daily living evaluated using the mMRC scale | Month 12 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obesity, Dyspnea, Bariatric Surgery
Effect of Growth Hormone (GH) on Cardiac Echos in GH Deficient Patients After Acromegaly Treatment

Study Overview
=================
Brief Summary
-----------------
The purpose of this research study is to study the effects of growth hormone (GH) replacement on the heart. The investigators will study these effects in people who have been cured of acromegaly and then have developed growth hormone deficiency (GHD, not enough growth hormone).

Official Title
-----------------
Effects of Physiologic Growth Hormone Administration on Echocardiographic Parameters in Subjects With Growth Hormone Deficiency Following Cure of Acromegaly

Conditions
-----------------
Acromegaly

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 18-75 history of acromegaly with biochemical cure growth hormone deficiency Exclusion Criteria: untreated thyroid disease within the past 3 months untreated adrenal insufficiency within the past 3 months uncontrolled hypertension congestive heart failure gonadal steroid therapy within the past 3 months pregnancy or nursing

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| GH deficient after acromegaly cure (on GH replacement)<br>Men and women with growth hormone deficiency following cure of acromegaly who are receiving growth hormone treatment. | |
| GH deficient after acromegaly cure (not on GH replacement)<br>Men and women with growth hormone deficiency following cure of acromegaly who are not receiving growth hormone treatment. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline in Echocardiographic Findings at One Year |  | baseline and one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acromegaly, growth hormone, growth hormone deficiency
A Phase 1 Single-Dose Escalation Study of PF-04308515 in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the safety, tolerability, pharmacokinetics (understanding how a drug is absorbed and moves through the body) and pharmacodynamics (understanding the effects of a drug on certain target sites of activity in the body).

Official Title
-----------------
A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Single-Dose Escalation Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04308515 in Healthy Volunteers

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Drug: PF-04308515
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy males between 18 and 55 years, inclusive Healthy females between 18 and 44 years, inclusive. Women need to be surgically sterile Exclusion Criteria: Evidence or history of clinically significant disease Post-menopausal women History of intolerance or significant adverse effects with glucocorticoids

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PF-04308515<br> | Drug: PF-04308515<br>* Oral solution/suspension 0.1 mg up to potentially 350 mg QD at a single dose.<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* Placebo solution/suspension to match active drug QD at a single dose.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the safety, tolerability and pharmacokinetics (PK) of single-rising doses of PF-04308515 |  | 1 day | 
| To characterize the pharmacodynamic (PD) effects of PF-04308515 on biomarkers |  | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Safety; tolerability; pharmacokinetics/pharmacodynamics
A Pilot Study of Shoulder Subluxation Treatment by Using the Self-Designed Surface Functional Electrical Stimulator

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the effects of the self-designed surface functional electrical stimulator on shoulder joint subluxation for stroke patients

Detailed Description
-----------------
Functional electrical stimulation (FES) is a common and effective therapeutic approach for clinical treatments of shoulder subluxation. By applying low-frequency electrical stimulation to the target muscle groups, improvements may be observed in terms of muscle strength, subluxation, and passive humeral lateral rotation of the shoulder joint. In order to overcome issues regarding the integration of an FES and a rehabilitation robot, group members have designed a customized FES system approved by medical safety regulations. Despite sharing identical specifications with commercial models, the approved 2-channel FES system provides better integrity and control when working with the upper extremity rehabilitation robot. In this study, three patients with unilateral shoulder subluxation will be recruited. Limited shoulder x-ray photos shall be taken before, during, and after the FES shoulder subluxation treatment for studying the effects.

Official Title
-----------------
Rehabilitation Robot for Upper Limbs, Component Project 2: Hybrid of FES and Rehabilitation Robot for Treatment of Shoulder Subluxation

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Device: Self-designed surface functional electrical stimulator


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: stroke (1-3 months) Brunnstrom Stage I-III single, unilateral Exclusion Criteria: aphasic shoulder impairment severe osteoporosis cardiac arrhythmias or having a pacemaker implanted abnormal cutaneous sensation at the target areas

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: shoulder FES treatment<br> | Device: Self-designed surface functional electrical stimulator<br>* Use the self-designed surface functional electrical stimulator to improve the shoulder joint subluxation.<br>* Other names: Self-designed surface functional electrical stimulation;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Upward migration index |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acromiohumeral distance |  | 1 year |
Management of an Imipenem-resistant Acinetobacter Baumannii Alert in a French University Hospital

Study Overview
=================
Brief Summary
-----------------
Colonization with imipenem-resistant Acinetobacter baumannii (IBA) is an unfavorable event for the patient, especially in intensive care. Indeed, it exposes the patient to the risk of developing serious infections, extremely difficult to treat. ABRI is a particularly resistant bacterium in the environment. When an ABRI epidemic occurs in a department as central to the hospital as a surgical resuscitation department, the control of such an event can be extremely complex. There are few clear and detailed descriptions in the literature of how to manage this type of outbreak, let alone an ABRI outbreak of this magnitude.

Official Title
-----------------
Management of an Imipenem-resistant Acinetobacter Baumannii Alert in a French University Hospital: A Retrospective Study

Conditions
-----------------
Acinetobacter Baumannii

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Major subject (≥18 years old) Patient having been hospitalized in the surgical resuscitation service of Hautepierre during the ABRI epidemic, between 01/05/2015 and 01/01/2019 inclusive and having been colonized and/or infected by ABRI (according to bacteriological results transmitted to the hygiene service). Subject having given his/her agreement, after information, for the reuse of his/her data for the purpose of this research Exclusion criteria: Subject having expressed his opposition to participate in the study Subject under guardianship or curatorship Subject under legal protection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective description of the management of an imipenem-resistant Acinetobacter baumannii outbreak that occurred from 2015 to 2019 in a surgical intensive care unit |  | Through study completion, an average of 5 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acinetobacter baumannii, Imipenem-resistant
Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia

Study Overview
=================
Brief Summary
-----------------
Primary Objective: To evaluate the effectiveness of amisulpride in Chinese patients with schizophrenia Secondary Objective: To evaluate the overall safety of amisulpride in Chinese patients with schizophrenia.

Detailed Description
-----------------
The study duration by subject will include a 8-week treatment period with 3 follow-up visits.

Official Title
-----------------
The Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia - A Prospective Open-Label Multicenter Study

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Drug: AMISULPRIDE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria : Satisfying International Classification of Disease-10 (ICD) diagnostic criteria of schizophrenia; Positive and Negative Syndrome Scale (PANSS) total score ≥ 60 Exclusion criteria: Refractory schizophrenia or Patients treated with sufficient clozapine for a minimum period of 6-8 weeks without improvement; Participation into another clinical trial within the last month; Patients previously or currently treated with amisulpride; Patients receiving clozapine within the past 1 month or treated with long-acting formulation of antipsychotic medication within the past 2 months; Patients receiving electric convulsive therapy or physical therapy within the past 1 month; Patients with coexisting severe systemic diseases; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Amisulpride<br>Patients are treated with Amisulpride referring to the dosage and usage section in Chinese Solian® PI. Amisulpride dosage is adjusted based on individual response and reaches the sufficiency within 1 week | Drug: AMISULPRIDE<br>* Pharmaceutical form: tablet Route of administration: oral<br>* Other names: Solian;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effective percentage (PANSS score reduced rate≥50%) |  | Week 8 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Early response rate (PANSS score reduced rate: at least 20%) |  | week 2 | 
| Positive and Negative Syndrome Scale (PANSS)-total score improvement |  | Baseline, Week 8 | 
| Clinical Global Impression Scale- Improvement (CGI-I) |  | Baseline, Week 8 |
Placement of the Double-Lumen Tube Without Fiberoptic Bronchoscope Assistance

Study Overview
=================
Brief Summary
-----------------
laryngoscope combined with chest CT in double lumen endotracheal tube accurate positioning

Detailed Description
-----------------
Comparing the traditional method of double lumen endotracheal tube intubation and laryngoscope combined with chest CT guide the precise localization of double lumen endotracheal tube

Official Title
-----------------
Placement of the Double-Lumen Tube Without Fiberoptic Bronchoscope Assistance

Conditions
-----------------
Therapeutic Procedural Complication

Intervention / Treatment
-----------------
* Device: laryngoscope and chest CT image
* Device: traditional method by experience


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI less than 35 kg/m2 ASA classifications of I-III, modified Mallampati classification 1 or 2 general anesthesia were included- Exclusion Criteria: Exclusion criteria included age younger than 18 yr ASA class IV or V Abnormalities of the heart, brain, liver, lung, kidney and coagulation functions-

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: laryngoscope and chest CT image<br>First,the operator calculate the distance between the carina and the glottis by CT image and make s marker on the double lumen endotracheal tube. Then the operator when inserted into the double lumen tube under the visualof laryngoscope until see marker just at the glottis. | Device: laryngoscope and chest CT image<br>* First,the operator calculate the distance between the carina and the glottis by CT image and make s marker on the double lumen endotracheal tube. Then the operator when inserted into the double lumen tube under the visualof laryngoscope until see marker just at the glottis<br>|
| Experimental: Traditional method by experience<br>Operator inserted the double lumen tube by experience | Device: traditional method by experience<br>* Operator inserted the double lumen tube by experience<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intubation Time |  | Ten minutes |
Novel Method of Surveillance in Barrett's Esophagus

Study Overview
=================
Brief Summary
-----------------
This study is being done to see how biomarkers (abnormalities in molecules of cells ) present in their Barrett's esophagus agree with results from surveillance biopsies; and to compare three different brush devices used to collect cells to see which of these 3 brush devices obtains a higher number of cells.

Detailed Description
-----------------
During an endoscopy done for clinical surveillance of your Barrett's Esophagus participants are randomized to one of three brush devices by random chance like a flip of a coin. This is being done to see if one collects more cells than the others. A soft brush will be used to collect cells from the lining of the esophagus, this is known as brush cytology. With the endoscope positioned in your esophagus, samples (biopsies) of lining of the esophagus will then be taken to determine the nature of the Barrett's mucosa in the same manner as for any patient undergoing routine surveillance endoscopy for Barrett's esophagus. A part of the specimen will be used to store tissue samples that can later be used.

Official Title
-----------------
Novel Method of Surveillance in Barrett's Esophagus

Conditions
-----------------
Barrett Esophagus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient age greater than 18 years of age Prior histological demonstration of Barretts Esophagus that is endoscopically visible with no dysplasia Low grade, high grade dysplasia or early esophageal cancer Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Barrett's, Esophagus, Reflux, dysplasia, adenocarcinoma
Evaluation of Apelin-13 and Apelin-36 in Women With Recurrent Pregnancy Loss

Study Overview
=================
Brief Summary
-----------------
Lower Apelin levels are associated with hypertensive disorders with pregnancy, yet no studies investigated its levels in recurrent pregnancy loss

Official Title
-----------------
Evaluation of Apelin-13 and Apelin-36 Concentrations in Women With Primary Unexplained Recurrent Pregnancy Loss

Conditions
-----------------
Recurrent Pregnancy Loss

Intervention / Treatment
-----------------
* Diagnostic Test: Apelin-13, Apelin-36


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnant women in first trimester negative antiphospholipid markers normal karyotype Exclusion Criteria: multiple pregnancy fetal malformations maternal diseases smoking or alcohol use history of or risk factors for preterm labor

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Recurrent pregnancy loss<br> | Diagnostic Test: Apelin-13, Apelin-36<br>* Serum levels of Apelin-13 and Apelin-36<br>|
| Healthy<br> | Diagnostic Test: Apelin-13, Apelin-36<br>* Serum levels of Apelin-13 and Apelin-36<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Apelin-13 and Apelin-36 | Serum levels of Apelin-13 and Apelin-36 | 1 year |